Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

CALGB 100801 (Alliance): A Phase II Multi-Center NCI Cooperative Group Study of the Addition of Azacitidine (AZA) to Reduced-Intensity Conditioning (RIC) Allogeneic Transplantation for High Risk Myelodysplasia (MDS) and Older Patients with Acute Myeloid Leukemia (AML): Results of a “test dose” Strategy to Target Busulfan Exposure

Ravi Vij, MD, Vera Hars, MS, William Blum, MD, Tsiporah B. Shore, Aaron P. Rapoport, MD, Thomas C. Shea, MD, Eva Hoke, Richard M. Stone, MD, Paula Friedman, Kouros Owzar, PhD, Steven M. Devine, MD

Blood (2014) 124 (21): 543.

https://doi.org/10.1182/blood.V124.21.543.543

Published: 2014

Journal Articles

A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502

Blood (2012) 120 (21): 230.

https://doi.org/10.1182/blood.V120.21.230.230

Published: 2012

Journal Articles

Surgical Mask Usage Reduces the Incidence of Parainfluenza Virus 3 in Recipients of Stem Cell Transplantation

Anthony D. Sung, MD, Julia A.M. Sung, MD, Kelly Corbet, Gloria Broadwater, MS, Vera Hars, MS, Ashley Zanter, NP, Nelson J. Chao, MD, Mitchell E. Horwitz, MD

Blood (2012) 120 (21): 462.

https://doi.org/10.1182/blood.V120.21.462.462

Published: 2012

Journal Articles

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

Philip L. McCarthy, MD, Kouros Owzar, PhD, Kenneth C. Anderson, Craig C. Hofmeister, MD, David Duane Hurd, MD, Hani Hassoun, MD, Sergio Giralt, MD, Edward A. Stadtmauer, MD, Paul G Richardson, MD, Daniel J. Weisdorf, MD, Ravi Vij, MBBS, MD, Jan S Moreb, MD, Natalie Scott Callander, MD, Koen Van Besien, MD, Teresa Gentile, MD, PhD, Luis Isola, MD, Richard T Maziarz, MD, Don A. Gabriel, MD, PhD, Asad Bashey, MD, PhD, Heather Landau, MD, Thomas Martin, MD, Muzaffar H. Qazilbash, MD, Denise Levitan, MD, Brian McClune, MD, Vera Hars, MS, John Postiglione, BA, Chen Jiang, PhD, Elizabeth Bennett, BS, Susan S Barry, BA, Linda Bressler, PharmD, Michael Kelly, MA, Michele Sexton, MS, Cara Rosenbaum, MD, Hari Parameswaran, MD, MS, Marcelo C Pasquini, MD, MS, Mary M. Horowitz, MD, MS, Thomas C. Shea, MD, Steven M Devine, MD, Charles Linker, MD

Blood (2010) 116 (21): 37.

https://doi.org/10.1182/blood.V116.21.37.37

Published: 2010

Journal Articles

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

Jonathan E. Kolitz, Stephen L. George, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. DeAngelo, Thomas C. Shea, Wendy Stock, Maria R. Baer, Vera Hars, Kati Maharry, Eva Hoke, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson, for the Cancer and Leukemia Group B

Blood (2010) 116 (9): 1413–1421.

https://doi.org/10.1182/blood-2009-07-229492

Published: 2010

Journal Articles

Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events.

Philip L. McCarthy, MD, Kouros Owzar, PhD, Edward A. Stadtmauer, MD, Sergio Giralt, MD, David D Hurd, MD, Hani Hassoun, MD, Craig Hofmeister, MD, Paul Richardson, M.D., Ph.D., Daniel J. Weisdorf, Marcelo C. Pasquini, MD, Vera Hars, PhD, Michael Kelly, B.S., John Postiglione, Susan Sutherland, Kenneth C. Anderson, MD, Charles Linker, MD

Blood (2009) 114 (22): 3416.

https://doi.org/10.1182/blood.V114.22.3416.3416

Published: 2009

Journal Articles

A Prospective Multicenter Phase II Trial of Pentostatin in Adult Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease (cGvHD): A Cancer and Leukemia Group B/Eastern Cooperative Oncology Group Study.

Sherif Farag, MD, PhD, Kouros Owzar, PhD, Vera Hars, PhD, Hillard M. Lazarus, MD, Edward A. Stadtmauer, MD, Steven M Devine, MD, Koen van Besien, MD, Charles Linker, MD

Blood (2009) 114 (22): 2238.

https://doi.org/10.1182/blood.V114.22.2238.2238

Published: 2009

Journal Articles

Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808.

Jonathan E. Kolitz, Vera Hars, Daniel J. DeAngelo, Steven L. Allen, Thomas C. Shea, Ravi Vij, Eva Hoke, Clara D. Bloomfield, Michael A. Caligiuri, Stephen L. George, Richard A. Larson

Blood (2007) 110 (11): 157.

https://doi.org/10.1182/blood.V110.11.157.157

Published: 2007

Journal Articles

A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808.

Jonathan E. Kolitz, Stephen L. George, Guido Marcucci, Ravi Vij, Bayard L. Powell, Steven L. Allen, Daniel J. De Angelo, Thomas Shea, Wendy Stock, Vera Hars, Eva Hoke, James W. Vardiman, Clara D. Bloomfield, Richard A. Larson

Blood (2005) 106 (11): 407.

https://doi.org/10.1182/blood.V106.11.407.407

Published: 2005

Journal Articles

Feasibility of Administering Oblimersen (G3139; Genasense) with Imatinib Mesylate in Patients with Imatinib Resistant Chronic Myeloid Leukemia (CML) - Cancer and Leukemia Group B Study 10107.

Meir Wetzler, MD, Daohai Yu, PhD, Olatoyosi Odenike, MD, Eric J. Feldman, MD, David D. Hurd, MD, Eva Hoke, Vera Hars, Richard A. Larson, MD

Blood (2005) 106 (11): 1097.

https://doi.org/10.1182/blood.V106.11.1097.1097

Published: 2005

NARROW

A Phase II Study of Allogeneic Transplantation for Older Patients with AML in First Complete Remission Using a Reduced Intensity Conditioning Regimen: Results From CALGB 100103/BMT CTN 0502

Surgical Mask Usage Reduces the Incidence of Parainfluenza Virus 3 in Recipients of Stem Cell Transplantation

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808

Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events.

A Prospective Multicenter Phase II Trial of Pentostatin in Adult Patients with Steroid-Refractory Chronic Graft-Versus-Host Disease (cGvHD): A Cancer and Leukemia Group B/Eastern Cooperative Oncology Group Study.

Phase III Trial of Immunotherapy with Recombinant Interleukin-2 (rIL-2) Versus Observation in Patients < 60 Years with Acute Myeloid Leukemia (AML) in First Remission (CR1): Preliminary Results from Cancer and Leukemia Group B (CALGB) 19808.

A Randomized Comparison of Induction Therapy for Untreated Acute Myeloid Leukemia (AML) in Patients < 60 Years Using P-Glycoprotein (Pgp) Modulation with Valspodar (PSC833): Preliminary Results of Cancer and Leukemia Group B Study 19808.

Feasibility of Administering Oblimersen (G3139; Genasense) with Imatinib Mesylate in Patients with Imatinib Resistant Chronic Myeloid Leukemia (CML) - Cancer and Leukemia Group B Study 10107.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only